Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2004

View Archived Issues

A study reveals a reduction in the incidence and mortality of stroke in Finland

Protein tyrosine phosphatase 1B inhibitors from Roche

New data on the efficacy of pegylated interferon alfa-2b in viral hepatitis

Novel proteasome inhibitor ER807446 demonstrates antitumor activity especially against large tumors

Inhibition of dopamine transport: a novel treatment for obesity

Antiatherosclerotic action of aminobisphosphonates

NF-kappaB inhibitor DHMEQ as treatment option for advanced urological cancer

Novel p38alpha MAP kinase inhibitors under study at Scios

Selective antagonist action on food intake not only mediated by NPY Y5 receptor

Two novel series of CDK inhibitors presented by Schering-Plough and Pharmacopeia

Agents combining antibacterial and beta-lactamase activity identified at Aventis Pharma

Cellular Genomics patent covers new protein kinase modulators

New GlyT-2 inhibitors in early development at NPS Allelix

NPS Allelix presents new GlyT-1 inhibitors and their use in schizophrenia and cognition disorders

Novartis claims new alpha7 nAChR agonists and their use

Highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Viral Therapeutics

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Transave

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Sirenade

Allergan to withdraw PEP-005 INDs, resubmission planned

Second phase III trial for regadenoson

SARS antibody sent to Sinovac for preclinical testing

GA-GCB enters clinical trial for Gaucher's disease

AlzheimAlert PMA accepted for filing

MedImmune to reacquire rights to FluMist and CAIV-T from Wyeth

EntreMed completes phase I trial with reformulated Panzem

Priority Healthcare becomes preferred specialty pharmacy provider of Apokyn

Celmed BioSciences sells neurology assets and technology platform

Fast track status for DB-289 for African sleeping sickness

New indication and strength approved for Hectorol

Nanogen completes acquisition of SynX

New positive opinion for Herceptin plus Taxotere in E.U.

PARP activation shown to be involved in diabetic neuropathy in mice and rats

Popular Stories

23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Today's news in brief
BioWorld
BioWorld briefs for June 17, 2025.
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 17, 2025.
New orphan drug, CSL’s garadacimab, cleared for hereditary angioedema
BioWorld
Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa...